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Abstract: Cost-effectiveness analysis has much conceptual attractiveness in priority
setting but is not used to its full potential to assist policy-makers on making choices in
health in developed or in developing countries. We call for a shift away from present
economic evaluation activities—that tend to produce ad hoc and incomparable economic
evaluation studies and, therefore, add little to the compendium of knowledge of
cost-effectiveness of health interventions in general—toward a more systematic
approach. Research efforts in economic evaluation should build on the foundations of
cost-effectiveness research of the past decades to arrive at an informative methodology
useful for national policy-makers. This strategy means that governments should steer
sectoral cost-effectiveness analysis to obtain systematic and comprehensive information
on the economic attractiveness of a set of new and current interventions, using a
standardized methodology and capturing interactions between interventions. Without
redirecting the focus of economic evaluation research, choosing in health care bears the
risk to remain penny-wise but pound-foolish.
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Cost-effectiveness analysis (CEA) has often been proposed
to guide priority setting in health but is not used to its full po-
tential in developed or in developing countries. In the absence
of central guidance, present research is dominated by studies
of new interventions compared with current practice, without
referral to the question of which interventions are most im-
portant to evaluate or the appropriateness of current practice.
This absence provides policy-makers with incomprehensive
or even misleading information to guide allocation decisions
in health.
If economic evaluation is to facilitate the process of
priority setting effectively, a clear vision of what needs to
be achieved and how this can be done is required. Here, we
propose a reformulation of economic evaluation appropriate
for the challenges in priority setting.
THE PRACTICE OF
COST-EFFECTIVENESS ANALYSIS
The technique of economic evaluation has much concep-
tual attractiveness in priority setting, because it relates the
achievable health gain of interventions with the costs of
these interventions. Thus, comparable costs per life years
gained or costs per quality-adjusted life year gained should
result. The central notion behind these exercises is that health
resources should be allocated across interventions and popu-
lation groups in such as way that the most health is generated
with the available budget. The health potential for the appli-
cation of economic evaluation is high. For example, an anal-
ysis for East Africa suggested that a reallocation of 50 per-
cent of the health budget (approximately US$5.20 per capita)
from interventions that are not cost-effective (i.e., have high
costs per life year gained) toward those that are most cost-
effective (i.e., have low costs per life year gained) could
result in a 64 percent increase in the years of life saved in the
region (1).
Economic evaluation of health-care technologies has
been formally institutionalized in the priority setting pro-
cess in several countries, including United Kingdom, The
Netherlands, Sweden, and New Zealand/Australia. In devel-
oping countries, the 1993 World Development Report “In-
vesting in Health” (8) sparked off significant interest in CEA
as an aid to priority setting in, for example, Mexico, India,
and a set of East and Northern African countries. However,
its impact on decision making is quite limited (14). Disagree-
ments over the theoretical bases of the methods and quality
of the available empirical evidence are important in this re-
spect (14). However, a more fundamental flaw, we argue, is
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the lack of central guidance in present economic evaluation
research. This finding causes at least three large drawbacks.
First, research priorities do rarely follow explicit criteria
such as burden of disease or potential societal benefit but typ-
ically result from ad hoc decisions, bottom-up approaches, or
interests of pharmaceutical companies. The resulting com-
pendium of CEA, therefore, is far from comprehensive and
may omit important interventions from the societal point of
view. For example, systematic reviews on effectiveness and
cost-effectiveness of brachytherapy for prostate cancer (11)
and growth therapy for children (2) could not identify any sin-
gle economic evaluation study, although the use of these in-
terventions is increasing. Likewise, Churchill and colleagues
(3) describe an “overall paucity of economic data available
for analysis and interpretation” in the area of depression. On
the other hand, a systematic review on the cost-effectiveness
of colorectal screening identified 180 potential articles (13).
This unbalanced set of evaluated interventions does not al-
low policy-makers to make allocation decisions across a dis-
ease area, let alone across the entire health sector. This is
reinforced by the emphasis of current CEA research to com-
pare new interventions with current practice, which ignores
the question of whether current interventions themselves are
cost-effective (10). Therefore, the current information may
lead to strategies and information that helps us to be penny-
wise but rarely corrects us in being pound-foolish.
Second, different CEA results are difficult to compare
because of the lack of standardization in study methodology.
A systematic review of CEA in rheumatoid arthritis remained
inconclusive because “studies lack consistency in their ac-
counting frameworks” (18). Similar conclusions were drawn
in the area of neurology (7) and diabetes mellitus (9).
Third, CEAs typically evaluate one intervention at a
time. Given that normally a health-care system delivers nu-
merous interventions, it is important to note that many inter-
actions between interventions in terms of costs and effects
will be present but cannot be accounted for in isolated CEAs.
For example, passive case detection and DOTS treatment in-
teracts with BCG vaccination in terms of costs and outcomes
(10).
A NEED FOR REGULATION
The collection of cost-effectiveness information on health
technologies can be seen as a public good that cannot be left
to individual (market) entities in the health-care sector and
for which collective action is required (19). Therefore, we see
a clear need for regulation in economic evaluation research
in defining research priorities, funding research, and facil-
itating technical guidance to the execution of the analysis.
Governments should foster economic analysis that results
in an overview of economic attractiveness of a comprehen-
sive set of new and current interventions. Only a systematic
approach will allow governments to maximize health gains
from a given budget by ceasing the funding of interventions
that are not cost-effective and by spending more resources
on interventions that are cost-effective.
Governmental action and institutional support (19) is re-
quired to initiate a systematic approach to economic analysis.
The public funding of so-called Horizon Scanning Systems—
that aim to identify and assess potentially significant tech-
nologies for health and health care that might become avail-
able on the market in 0 to 5 years time—in many Western
countries is one important step forward in the systematic in-
terpretation of cost-effectiveness evidence (5). However, we
argue that national public bodies should also regulate and
coordinate the initiation and execution of economic evalua-
tion research to better address information needs of policy-
makers, as exemplified by the National Institute of Clinical
Excellence (NICE) in the United Kingdom (6) and the de-
mand for a similar body in The Netherlands (15)
DO NOT LET THE PERFECT BE
THE ENEMY OF THE GOOD
The required cost-effectiveness information should be seen
as only one input into the policy debate on priorities, which
includes several other criteria reflecting goals of health sys-
tems (10). Given the multiple goals in health care, rather than
a formulaic approach, economic analysis is probably most
powerful when it is ultimately used to classify interventions
into broad groups of cost-effectiveness: those that are very
cost-effective, cost-effective, and not cost-effective. The use
of cost-effectiveness thresholds basically reflect this way of
thinking by setting a maximum cost per QALY, which is
meant to separate the cost-effective from the cost-ineffective
interventions (4). In this context, instead of striving for de-
tailed estimates, which often result from prospective analysis,
analysts can suffice to provide results that prove the “order
of magnitude” of cost-effectiveness of interventions.
SECTORAL COST-EFFECTIVENESS
ANALYSIS
A national compendium on cost-effectiveness would require
the joint evaluation of interventions in a single exercise
to avoid methodological inconsistencies and the neglect of
interactions between diseases and/or interventions. Such a
comprehensive approach to economic evaluation already has
been proposed by Weinstein and Stason (21) in their founda-
tions of CEA, more than 25 years ago, and has been labeled
sectoral CEA by others (10;16). Sectoral CEA is essentially
the result of a combination of many individual CEA, but
central guidance and standardization allow the integration
of studies and comparability of results. The resulting cost-
effectiveness database, thereby, is much different from many
published cost-effectiveness league tables, which essentially
face the same limitations as the economic analyses they are
based on (as discussed above). Given its conceptual attrac-
tiveness, it is striking that only a few applications of sectoral
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CEA exist. Work in Western countries includes that of the
Oregon Health Services Commission (12), the Harvard Life
Saving Project (20) in the United States, and—to a certain
extent—NICE in the United Kingdom (6). For developing
countries, the World Bank Health Sector Priorities Review
(8) and the WHO-CHOICE (CHOosing Interventions that are
Cost-Effective) project (17) carried out global and regional
analysis.
CONCLUSION
The need to make choices in health is visible but present eco-
nomic evaluation research is incapable to support decisions.
We call for a shift away from present economic evaluation
activities—that tend to produce ad hoc and incomparable
economic evaluation studies and, therefore, add little to the
compendium of knowledge of cost-effectiveness of health in-
terventions in general—toward a more systematic approach
to economic evaluation research. Countries that have the fi-
nancial and analytical means may wish to adopt a NICE-like
approach, whereas resource-poor countries may adopt a more
rudimentary approach and draw their knowledge from global
and regional databases. It is time to expand our research ef-
forts in economic evaluation and build on the foundations of
cost-effectiveness research of the past decades to arrive at an
informative methodology useful for national policy-makers.
Without redirecting the focus of this research, choosing in
health-care bears the risk to remain penny-wise but pound-
foolish.
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